Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Prevention and risk

Reviewed as evidence on: Epilepsy / seizures and young-onset (<65) dementia risk 5 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Multimorbidity-the co-occurrence of two or more chronic health conditions-affects > 86% of people with dementia. It is associated with cognitive and functional decline, reduced health-related quality of life, increased health-care use, and higher mortality. The relationship between multimorbidity and dementia is potentially bidirectional; conditions such as hypertension and diabetes increase the risk of developing dementia, and cognitive impairment can complicate their management. This complexity presents challenges in health care and research, affecting treatment decisions and often leading to the exclusion of these individuals from clinical trials. Understanding multimorbidity through long-term prospective studies is crucial to clarify its relationship with dementia. Investigating specific disease combinations, environmental and genetic factors, and their impacts on cognitive health will guide the development of effective prediction models and inclusive intervention strategies for diverse global populations across the life course. HIGHLIGHTS: Multimorbidity affects > 86% of individuals with dementia, worsening outcomes. The relationship between multimorbidity and dementia is potentially bidirectional. Chronic conditions hinder dementia management and clinical trial inclusion. Life-course multimorbidity research is key to dementia risk reduction strategies. Prospective studies are needed to improve prediction models and interventions.

Key findings

Why it matters

This review reports that multimorbidity affects more than 86% of people with dementia and is tied to faster cognitive and functional decline, lower quality of life, more health-care use, and higher mortality. It calls for long-term prospective studies to clarify the relationship, so it offers no treatment, cure, or prevention at this stage.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 41 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.7 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 25.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 41 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Vidyani Suryadevara: h-index 14 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 31 institution(s) in 9 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40755143)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Stirland, L., Choate, R., Zanwar, P., Zhang, P., Watermeyer, T., Valletta, M., et al. (2025). Multimorbidity in dementia: Current perspectives and future challenges. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70546

Vancouver

Stirland L, Choate R, Zanwar P, Zhang P, Watermeyer T, Valletta M, et al. Multimorbidity in dementia: Current perspectives and future challenges. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70546. PMID: 40755143.

BibTeX

@article{stirland2025-40755143,
  author  = {Stirland, Lucy and Choate, Radmila and Zanwar, Preeti and Zhang, Panpan and Watermeyer, Tamlyn and Valletta, Martina and Torso, Mario and Tamburin, Stefano and others},
  title   = {{Multimorbidity in dementia: Current perspectives and future challenges}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70546},
  pmid    = {40755143},
  url     = {https://doi.org/10.1002/alz.70546}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Prevention and risk

Also tagged “epilepsy-and-young-onset-dementia”

5 studies in the library carry the topic tag “epilepsy-and-young-onset-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →